Phenotypic Exploration of Autism Spectrum Disorders Retrospective and Prospective Data
EXPECT
1 other identifier
observational
1,500
1 country
1
Brief Summary
Autism Spectrum Disorders (ASD) are a heterogeneous group of severe developmental abnormalities of the nervous system characterized by deficits in social interaction and verbal and nonverbal communication affecting approximately 1% of the general population. In 5-40% of cases, genetic factors are identified as the cause of these disorders. Despite this unique definition and the advancement of techniques, ASD is still a clinically and genetically heterogeneous condition, as several hundred genes have been identified to date. Primary Objective and Endpoint Primary Objective: Exploration of phenotypic heterogeneity in patients with ASD. Primary endpoint:
- Routine Care Clinical Investigation Criteria.
- Scores on assessment scales,
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 7, 2021
CompletedFirst Posted
Study publicly available on registry
June 11, 2021
CompletedStudy Start
First participant enrolled
July 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
April 18, 2022
May 1, 2021
5 years
June 7, 2021
April 15, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
The main objective is to better understand the phenotypic heterogeneity of Autism Spectrum Disorder (ASD).
DSM5 (Diagnostic statistical Manual of Mental disorders) Autism diagnostic scales
12 months
Interventions
No intervention
Eligibility Criteria
child (age \<18 years) with Autism Spectrum Disorder
You may qualify if:
- child (age \<18 years) with Autism Spectrum DisorderAutism Spectrum Disorder
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Robert Debré
Paris, 75019, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Richard DELORME, PhD
Assistance Publique - Hôpitaux de Paris
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 7, 2021
First Posted
June 11, 2021
Study Start
July 1, 2021
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
July 1, 2027
Last Updated
April 18, 2022
Record last verified: 2021-05
Data Sharing
- IPD Sharing
- Will not share